Livsayis™ (cemdisiran) Approved by the FDA as First and Only siRNA Therapy in Generalized Myasthenia Gravis and Only Treatment with Four-Times-a-Year Subcutaneous Dosing
The FDA approved Regeneron's Livsayis (cemdisiran) for generalized myasthenia gravis, the first siRNA therapy for this condition. Phase 3 trial results showed significant improvements over placebo. The drug is administered subcutaneously four times a year, but carries a Boxed Warning for serious infections.
How this was made
The 30-second read
Why it matters
Regulatory approval provides a new revenue stream and positions Regeneron in the growing RNA‑therapy space, likely supporting its stock price.
Market read
The approval is a material regulatory event for Regeneron, creating a fresh catalyst for the stock and potentially influencing the biotech sector.
What to watch
Potential competition from other gMG treatments and the need for extensive physician education on subcutaneous dosing.
Background
Regeneron (NASDAQ:REGN) expands its portfolio with Livsayis, the first siRNA therapy approved for generalized myasthenia gravis, showing 2.3‑point MG‑ADL improvement over placebo.
Ticker impact
FDA approved Livsayis (cemdisiran) for generalized myasthenia gravis, adding a first‑in‑class siRNA therapy to Regeneron's pipeline.
likely upward pressure as investors price in future sales potential
First siRNA therapy for gMG, strong Phase 3 data, and limited launch guidance create a clear upside catalyst.
Market effects
May boost broader biotech/neurology sector as investors anticipate similar RNA‑based therapies.
U.S. biotech stocks could see modest gains; limited immediate effect on other regions.
Regeneron's approval highlights RNA therapeutics, potentially influencing global biotech funding trends.
Counterpoint
Boxed warning and REMS program could limit uptake; sales timeline and reimbursement uncertainty may temper upside.
Key entities
- companyRegeneron Pharmaceuticals Inc.
US‑listed biotech company receiving FDA approval for Livsayis.
- productLivsayis (cemdisiran)
First siRNA therapy approved for generalized myasthenia gravis.




